Valutazione del rischio cardiometabolico tramite tecniche neuroradiologiche avanzate ed algoritmi di intelligenza artificiale in pazienti con diabete, Mild Cognitive Impairment e malattia di Alzheimer (AD), per la diagnosi precoce e una migliore prognosi di AD

Abstract

Alzheimer’s disease (AD) is strongly influenced by cardiometabolic risk factors. The RICAMI project involves a prospective study on 80 subjects undergoing a 6-month anti-inflammatory nutritional treatment.
The project aims to validate cardiometabolic, morphological, and vascular neuroradiological risk markers using MRI in patients with Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). At the same time, it intends to develop new AI algorithms capable of assessing brain trophism and analyzing changes in cerebral blood flow before and after the adoption of an anti-inflammatory diet. In addition, the research focuses on designing advanced AI tools for early diagnosis and improved prognosis of Alzheimer’s Disease, through the integration of the data collected.

Partner

Università degli Studi di Palermo